首页> 外文期刊>Journal of Bangladesh College of Physicians and Surgeons >Effect of Low Dose Oral Contraceptive Pill on Coagulation Status in Women with Normal and Low Body Mass Index
【24h】

Effect of Low Dose Oral Contraceptive Pill on Coagulation Status in Women with Normal and Low Body Mass Index

机译:低剂量口服避孕药对正常和低体重指数女性凝血状态的影响

获取原文
           

摘要

Background: Oral contraceptive pill (OCP) is widely used by millions of women of various socioeconomic conditions.Use of low dose oestrogen and newer progesterone in OCP now associated with less thromboembolic and cardiovascular risk. The safety aspects of these pills had not been investigated in details in malnourished women of developing countries. In the present study the effects of the pillson coagulation status have been studied.Objective: To explore the effect of the most widely used low dose OCP (Shukhi) on coagulation status of Bangladeshi women with normal and low BMI(Body Mass Index). Materials and Methods: The study population group (n=29) comprised of women with normal BMI and the underweight group (n=11,BMI<18.5). Both groups use low dose OCP(30μg ethinyl estradiol and 150μg levonorgestrel) for 6-60 months. The coagulation status were assessed as follows: Plasma Fibrinogen, Prothrombin time and Platlete aggregation and Anticoagulation statuseg: AntithrombinIII (ATIII).Result:Coagulation status showed no significant difference in platelet aggregation between the groups. Plasma fibrinogen median value (450mg/dl) just exceeded the upper limit of reference range (normal range: 200-400mg/dl) in normal BMI. In contrast, the corresponding value in the low BMI (318mg/ dl) group was almost at the middle of the reference range. A significantly prolonged prothrombin time (13.80 seconds) was found in the low BMI group (p=0.058); values were still within the reference range (10-14 seconds). No significant correlation existed between plasma fibrinogen, prothrombin time and platelet aggregation in normal BMI or low BMI groups. Antithrombin IIIactivity in normal BMI group was 108% and in low BMI group it was 105%. Atendency of positive correlation existed between antithrombin III activity and BMI in low BMI pill users (r=0.591,p=0.072).Conclusion:The study suggested that a) Reported risk of procoagulant or thromboembolic changes in pill users is lower in low BMI &normal BMI and b) Low BMI users showed significantly longer prothrombin time due to the effect of malnutrition itself or due to the effect of pills in this nutritional background.J Bangladesh Coll Phys Surg 2017; 35(1): 3-8
机译:背景:口服避孕药(OCP)已被数百万具有各种社会经济状况的女性广泛使用,在OCP中使用低剂量雌激素和更新的孕激素现已减少了血栓栓塞和心血管疾病的风险。尚未对发展中国家营养不良的妇女对这些药的安全性进行详细调查。目的:探讨最广泛使用的低剂量OCP(Shukhi)对BMI正常和BMI(身体质量指数)低的孟加拉国妇女凝血状态的影响。材料和方法:研究人群组(n = 29)包括BMI正常的女性和体重不足组(n = 11,BMI <18.5)。两组均使用低剂量OCP(30μg乙炔雌二醇和150μg左炔诺孕酮)治疗6-60个月。凝血状态评估如下:血浆纤维蛋白原,凝血酶原时间和血小板凝集和抗凝状态,例如:抗凝血酶III(ATIII)。血浆纤维蛋白原中值(450mg / dl)刚刚超过正常BMI中参考范围的上限(正常范围:200-400mg / dl)。相反,低BMI(318mg / dl)组的相应值几乎处于参考范围的中间。在低BMI组中,凝血酶原时间显着延长(13.80秒)(p = 0.058)。值仍在参考范围内(10-14秒)。在正常BMI组或低BMI组中,血浆纤维蛋白原,凝血酶原时间与血小板聚集之间无显着相关性。正常BMI组抗凝血酶III活性为108%,低BMI组为105%。低体重指数药丸使用者的抗凝血酶III活性与体重指数呈正相关(r = 0.591,p = 0.072)。结论:研究表明:a)低体重指数与正常人群中,丸剂使用者发生促凝或血栓栓塞变化的风险较低。 BMI和b)低BMI使用者由于营养不良本身或在这种营养背景下服用药丸的影响,凝血酶原时间显着延长.J Bangladesh Coll Phys Surg 2017; 35(1):3-8

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号